We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Arash Rashidi, MD

Arash Rashidi, MD

  • Specialty: Nephrology, Hypertension, Nephrology-OncoNephrology
    View Expertise
  • Primary Location: 29325 Health Campus Dr (18 mi.)
    Other Locations
  • Languages Spoken: English, Turkish, Farsi

Office Locations

UH Ohio Medical Group (18 mi.)

29325 Health Campus Dr
Ste 3
Westlake, OH 44145

DO Mather 1600 (0 mi.)

11100 Euclid Ave
Mather Ste 1600
Cleveland, OH 44106

UH Cleveland Medical Center (0 mi.)

11100 Euclid Ave
1st Floor
Cleveland, OH 44106

UH Minoff Health Center at Chagrin Highlands (7 mi.)

3909 Orange Pl
Ste 3100
Beachwood, OH 44122

Biography: Arash Rashidi, MD


  • Chronic Kidney Disease (CKD)
  • Fluid and Electrolyte Disorders
  • Hypertension
  • Onco-Nephrology


  • Director, Onco-Nephrology Program, UH Cleveland Medical Center
  • Clinical Associate Professor, CWRU School of Medicine

Certifications & Memberships

  • Nephrology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine


Fellowship | Interventional Nephrology
Interventional Nephrology - Emory University School Of Medicine (2007 - 2008)

Fellowship | Nephrology
Nephrology - Uh Case Medical Center (2005 - 2007)

Residency | Internal Medicine
Internal Medicine - Fairview Hospital (2002 - 2005)

Medical Education
Urmia Univeristy (West Azerbaijan University of Medical Sciences) (1997)


Arash Rashidi, MD, is the director of the Onco-Nephrology Program at University Hospitals and a clinical associate professor of medicine at Case Western Reserve University School of Medicine. He is board-certified in internal medicine and nephrology and hypertension.

Dr. Rashidi earned his medical degree at the Urmia University of Medical Sciences in Urmia, Iran. He did residency training in internal medicine at Shahid Beheshty University of Medical Sciences in Tehran, Iran, and an additional three years at Cleveland Clinic. He went on to complete a nephrology and hypertension fellowship at University Hospitals/Case Western Reserve University followed by an interventional nephrology fellowship at Emory University School of Medicine in Atlanta.

Dr. Rashidi returned to UH in 2014 and became director of Onco-Nephrology Program in 2018. Under his leadership, the Onco-Nephrology Program at UH has become one of the most respected programs in the nation.

Dr. Rashidi has published numerous peer-reviewed articles, abstracts, books and book chapters. He also has served on the editorial board of several prominent medical journals. Additionally, Dr. Rashidi has been an invited speaker/lecturer at several local, national and international meetings and conferences. He has received several awards throughout his career.

Dr. Rashidi is one of the founding members, an executive board member, and past president of the American Society of Onconephrology. Other professional organizations that Dr. Rashidi is a member of include the American College of Physicians, the American Heart Association Council on Kidney in Cardiovascular disease, the American Society of Nephrology, and National Kidney Foundation.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Arash Rashidi did not disclose any Outside Relationships with Industry.